Charles River Laboratories International, Inc.
CRL
$163.71
-$0.40-0.24%
NYSE
| 06/28/2025 | 03/29/2025 | 12/28/2024 | 09/28/2024 | 06/29/2024 | |
|---|---|---|---|---|---|
| Revenue | -1.21% | -2.16% | -1.92% | -3.67% | -2.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.21% | -2.16% | -1.92% | -3.67% | -2.41% |
| Cost of Revenue | -0.13% | 0.24% | 1.19% | -1.40% | 0.16% |
| Gross Profit | -3.15% | -6.42% | -7.31% | -7.54% | -6.73% |
| SG&A Expenses | 4.53% | -2.67% | -2.09% | -3.63% | -6.20% |
| Depreciation & Amortization | 5.37% | 3.25% | -6.96% | -13.10% | -12.60% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.02% | -0.27% | 0.18% | -2.33% | -1.72% |
| Operating Income | -13.69% | -12.98% | -13.48% | -10.78% | -6.08% |
| Income Before Tax | -103.36% | -94.52% | -83.98% | -16.01% | -13.94% |
| Income Tax Expenses | -50.57% | -45.71% | -32.79% | -33.84% | -31.31% |
| Earnings from Continuing Operations | -114.56% | -105.17% | -94.74% | -10.93% | -9.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 48.55% | 69.36% | 46.26% | 24.51% | 30.90% |
| Net Income | -115.18% | -105.69% | -95.32% | -10.77% | -8.78% |
| EBIT | -13.69% | -12.98% | -13.48% | -10.78% | -6.08% |
| EBITDA | 0.58% | -5.36% | -4.99% | -4.40% | -1.66% |
| EPS Basic | -115.64% | -107.41% | -98.13% | -13.56% | -11.44% |
| Normalized Basic EPS | -19.01% | -19.04% | -16.42% | -4.67% | -2.90% |
| EPS Diluted | -115.90% | -107.62% | -98.35% | -13.46% | -11.39% |
| Normalized Diluted EPS | -18.77% | -18.89% | -16.33% | -4.56% | -2.80% |
| Average Basic Shares Outstanding | -1.57% | -0.24% | 0.30% | 0.58% | 0.73% |
| Average Diluted Shares Outstanding | -1.91% | -0.51% | 0.10% | 0.46% | 0.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |